Results of masitinib study in metastatic melanoma
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
AB Science Corporate Presentation
22/07/2019 – AB Science Corporate Presentation – July 2019
Summary of the webconference held on July 8, 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
July 8 2019 web conference presentation
08/07/2019 – AB Science web conference presentation
Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD
08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure
04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
Results of interim analysis for masitinib in Alzheimer’s Disease
26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
June 14 2019 web conference presentation
14/06/2019 – AB Science web conference presentation
Positive IDMC recommendation following interim analysis in pancreatic cancer
12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer
Upcoming news flow
10/06/2019 – AB Science is providing the upcoming news flow of the Company